Physical activity is a powerful lifestyle factor that on average reduces the risk for developing Type II diabetes. Further, a lack of fitness has been shown to be a better predictor of illness and premature death than some other factors that many people seem more concerned about, such as high blood pressure.
However, whilst some individuals respond very well to exercise training, with regard to improvements in health and fitness, others do not respond at all. We, for example, have previously shown that following supervised endurance exercise training, 20% of subjects show no change in fitness and 30% demonstrate no improvement in insulin sensitivity.
The objective of Metapredict is to discover if individualised lifestyle strategies can be developed to fight or prevent metabolic diseases such as obesity, diabetes and cardiovascular problems.
Biomarkers are measureable characteristics that can be used as an indicator of whether the body is healthy or is in a particular diseased state. The Metapredict project plans to identify molecular biomarkers and study the response to exercise and training. The concept is that by using molecular profiling of blood/muscle samples we will develop personalised lifestyle intervention tools.
Our research is supported by EU-funding of €6 million and is carried out by an international multidisciplinary research consortium including medical staff, physiologists, and experts in genetics, genomics, informatics, and metabolism.
Read More >>
Metapredict's co-ordinator Professor Jamie Timmons was invited to feature in an American Association for the Advancement of Science (AAAS) webinar. The webinar, entitled “Winning the Translational Race: Making Good Choices in Biomarker Assay Development for the Clinic?”, brought Prof. Timmons together with Prof Richard Kennedy from Almac Diagnostics. The two thought-leaders each gave a short presentation followed by a Q&A session.
Follow the link to listen to the webinar recording or download the transcript.
Winning the Translational Race: Making Good Choices in Biomarker Assay Development for the Clinic